# US 10,479,827 B2 · Monoclonal antibody reacting with glycopeptide, and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,479,827 B2 - Document ID: US10479827B2 - Status: Granted - Kind: B2 - Application number: 15/608,015 - Filed: 2017-05-30 - Published: 2017-11-30 - Granted: 2019-11-19 - Earliest claimed: 2016-05-31 - Assignees: Sysmex Corporation - Applicants: Sysmex Corporation - Inventors: Yukiko Kataoka; Tsuyoshi Nomura; Koji Fukagawa; Yuriko Egashira; Yukiko Higa - Web page: https://patentgrep.com/patent/US10479827B2 ## CPC - C07K 16/18: against material from animals or humans - C07K 16/303: {Liver or Pancreas} - C07K 16/3076: {against structure-related tumour-associated moieties} - G01N 33/57585: {involving compounds identifiable in body fluids} - G01N 33/689: {related to pregnancy or the gonads} - C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/565: Complementarity determining region [CDR] - G01N 2333/471: Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein - G01N 2400/02: involving antibodies to sugar part of glycoproteins - G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Disclosed is a monoclonal antibody reacting with a glycopeptide, wherein the glycopeptide contains a core fucose moiety and at least 4 contiguous amino acid residues that are located on the C-terminal side of a glycosylated asparagine moiety, and both of the core fucose moiety in the glycopeptide and an amino acid residue that is located apart by at least three amino acid residues from the C-terminal of the glycosylated asparagine moiety in the glycopeptide are epitopes for the antibody. ## Claims ### Claim 1 A monoclonal antibody, which reacts with a glycopeptide of formula (1) (SEQ ID NO: 13), does not react with a glycopeptide of formula (2) (SEQ ID NO: 14), and does not react with a glycopeptide of formula (3) (SEQ ID NO: 15): wherein said antibody comprises a heavy chain comprising three complementarity-determining regions (CDRs), which CDRs comprise the amino acid sequences of SEQ ID NOs: 1-3, respectively, and wherein said antibody further comprises a light chain comprising three CDRs, which CDRs comprise the amino acid sequences of SEQ ID NOs: 4-6, respectively. ### Claim 2 (depends on 1) The antibody of claim 1, wherein the antibody does not react with a glycopeptide of formula (4) (SEQ ID NO: 16) ### Claim 3 (depends on 1) The antibody of claim 1, which further reacts with fucosylated α-fetoprotein (AFP). ### Claim 4 (depends on 1) The antibody of claim 1, wherein the antibody reacts, in the presence of 0.025% by mass or less of SDS, with fucosylated α-fetoprotein (AFP) that has been pretreated by a solution comprising 0.03% by mass or more of SDS. ### Claim 5 (depends on 1) The antibody of claim 1, wherein the antibody reacts with fucosylated α-fetoprotein (AFP) which has been pretreated by a solution comprising 2% by mass of SDS and 50 mM of DTT. ### Claim 6 (depends on 1) The antibody of claim 1, wherein the antibody does not react with a non-fucosylated α-fetoprotein (AFP) which has been pretreated by a solution comprising 2% by mass of SDS and 50 mM of DTT. ### Claim 7 (depends on 1) A reagent kit, comprising a fucosylated α-fetoprotein (AFP)-capturing antibody, a fucosylated AFP-detecting antibody and a solid support, wherein at least one of the fucosylated AFP-capturing antibody and the fucosylated AFP-detecting antibody is the antibody of claim 1. ### Claim 8 (depends on 1, 7) The kit of claim 7, wherein the fucosylated AFP-capturing antibody is the antibody of claim 1. ### Claim 9 (depends on 7) The kit of claim 7, further comprising a pretreatment solution comprising 0.03% by mass or more of SDS. ### Claim 10 (depends on 7) The kit of claim 7, wherein the solid support is particles, a film, a microplate, a microtube or a test tube. ### Claim 11 A monoclonal antibody, which reacts with a glycopeptide of formula (1) (SEQ ID NO: 13), does not react with a glycopeptide of formula (2) (SEQ ID NO: 14), and does not react with a glycopeptide of formula (3) (SEQ ID NO: 15): wherein said antibody comprises a heavy chain comprising three CDRs, which CDRs comprise the amino acid sequences of SEQ ID NOs: 7-9, respectively, and wherein said antibody further comprises a light chain comprising three CDRs, which CDRs comprise the amino acid sequences of SEQ ID NOs: 10-12, respectively.